By George Ongkojoyo 
Metastatic progression remains the primary cause of mortality in breast cancer patients, driven by the dissemination of rare, highly resilient cells that travel through the bloodstream to colonize distant organs. In a landmark study that promises to redefine the landscape of personalized oncology, a collaborative team from the German Cancer Research Center (DKFZ), the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), and the National Center for Tumor Diseases (NCT) Heidelberg has achieved a world-first: the stable cultivation of tumor organoids directly from the blood of breast cancer patients. This technological leap allows researchers to study "circulating tumor cells" (CTCs) in a controlled laboratory environment, bypassing the need for animal models and providing a real-time window into the molecular mechanisms of therapy resistance.
The Critical Role of Circulating Tumor Cells in Metastasis
Breast cancer is the most diagnosed malignancy among women worldwide, with the World Health Organization reporting approximately 2.3 million new cases and 685,000 deaths annually. While localized breast cancer now boasts a five-year survival rate exceeding 90% in many developed nations, the prognosis for metastatic (Stage IV) disease remains significantly more guarded, with survival rates hovering around 30%. The disparity lies in the biological behavior of metastases—secondary tumors in the lungs, liver, brain, or bones that are often heterogenous and resistant to conventional therapies.
At the heart of this "metastatic cascade" are circulating tumor cells. These cells detach from the primary tumor, enter the circulatory system, and navigate the hostile environment of the blood before extravasating into new tissues. Andreas Trumpp, Head of the Division of Stem Cells and Cancer at the DKFZ and Director of HI-STEM, has spent years identifying these cells as the "germ cells" of metastasis. However, CTCs are exceptionally rare; a single milliliter of blood containing billions of red and white blood cells may harbor only a handful of tumor cells. This scarcity has historically made them nearly impossible to study in vitro, forcing researchers to rely on patient-derived xenografts (PDX)—a process where human cells are injected into immunodeficient mice. While effective, the PDX model is time-consuming, expensive, and often fails to reflect the rapid evolution of a patient’s disease.
A Methodological Breakthrough: From Liquid Biopsy to Living Organoids
The Heidelberg team’s success in growing CTCs as three-dimensional organoids—essentially "mini-tumors" in a dish—marks a paradigm shift. By refining the culture conditions to mimic the physiological environment of the human body, the researchers were able to induce these rare cells to proliferate into stable, multicellular structures that retain the genetic and functional characteristics of the patient’s original cancer.
This direct cultivation method offers several advantages over traditional tissue biopsies. Surgical biopsies are invasive and often cannot be performed repeatedly, especially when metastases are located in inaccessible areas like the brain. In contrast, blood samples—referred to as "liquid biopsies"—are minimally invasive and can be collected at multiple intervals throughout a patient’s treatment journey.
"To understand how tumor cells become resistant to therapies, we need tumor material from different time points in the course of the disease," explains Roberto Würth, the study’s first author. "The ability to grow these cells directly from a simple blood draw allows us to observe the cancer’s evolution in real-time, providing a dynamic map of how the disease responds to specific drugs."
Deciphering the Molecular Blueprint of Resistance: NRG1 and the HER Receptor Family
Beyond the technical feat of cultivation, the research team utilized these organoids to uncover the specific signaling pathways that allow breast cancer cells to survive in the bloodstream and resist treatment. By integrating their findings with data from the CATCH (Comprehensive Analysis of Tumor Characteristics in Heidelberg) clinical registry trial, the researchers identified a critical survival axis involving the protein Neuregulin 1 (NRG1).
NRG1 acts as a potent biological "fuel" for the cancer cells. It binds to the HER3 receptor on the cell surface, which then partners with the well-known HER2 receptor to trigger internal signaling cascades. These pathways promote cell division and prevent apoptosis (programmed cell death), effectively shielding the CTCs from the immune system and chemotherapy.
However, the researchers discovered a secondary layer of complexity: the "bypass" mechanism. When the NRG1-HER2/3 pathway is inhibited—either by drug intervention or a lack of ligands—the cancer cells do not necessarily die. Instead, they activate an alternative route controlled by the Fibroblast Growth Factor Receptor 1 (FGFR1). This molecular flexibility explains why many patients who initially respond to HER2-targeted therapies, such as trastuzumab (Herceptin), eventually experience a relapse. The cancer simply "switches tracks" to maintain its growth.
Preclinical Validation and the Promise of Dual Inhibition
Using the patient-derived organoids as a testing ground, the Heidelberg team demonstrated that a single-target approach is often insufficient. In their experiments, blocking only the HER receptors or only the FGFR1 receptor allowed a portion of the tumor cells to survive. However, when a combined blockade was applied—targeting both the NRG1-HER2/3 axis and the FGFR pathway simultaneously—the researchers observed a dramatic cessation of cell proliferation followed by widespread cell death.
This discovery provides a clear rationale for new combination therapy protocols. Because the organoids are grown from the cells of individual patients, they can be used to perform "functional precision medicine." Clinicians could potentially test a battery of FDA-approved drugs on a patient’s specific mini-tumors to determine which combination is most effective before the patient ever receives the treatment. This reduces the "trial and error" period often associated with late-stage cancer care, sparing patients from the toxicity of ineffective drugs.
Chronology of Research and Institutional Collaboration
The success of this project is the result of a decade-long investment in stem cell and metastasis research within the Heidelberg medical cluster.
- 2008: HI-STEM is founded as a partnership between DKFZ and the Dietmar Hopp Foundation, focusing on the role of stem cells in cancer.
- Early 2010s: Andreas Trumpp’s laboratory identifies specific subsets of CTCs with "metastasis-initiating" potential, distinguishing them from the broader population of non-viable circulating cells.
- 2015–2020: The CATCH trial begins at NCT Heidelberg, creating a massive repository of genetic and clinical data from breast cancer patients.
- 2021–2023: The research team refines the medium and scaffolding required to grow CTCs into 3D organoids without the use of animal intermediaries.
- 2024: The team publishes their findings, detailing the NRG1-HER3-FGFR1 resistance loop and the success of the dual-inhibition strategy in lab models.
This timeline highlights the necessity of long-term interdisciplinary collaboration. The project bridged the gap between basic laboratory science at the DKFZ, the translational infrastructure of HI-STEM, and the clinical expertise of the NCT.
Broader Implications for Global Oncology
The implications of this research extend far beyond breast cancer. The ability to cultivate CTC-derived organoids could theoretically be applied to other solid tumors that metastasize via the blood, including lung, prostate, and colorectal cancers.
Furthermore, the study contributes to the growing field of "liquid biopsy" technology. While current liquid biopsies primarily focus on detecting circulating tumor DNA (ctDNA) to identify genetic mutations, the cultivation of whole cells (CTCs) allows for functional testing. While DNA can tell you that a mutation exists, an organoid can show you how that mutation actually behaves when exposed to a drug.
"The possibility of cultivating CTCs as tumor organoids is a decisive breakthrough," says Andreas Trumpp. "On this basis, we can develop new treatments that specifically kill resistant tumor cells. Another conceivable approach is to adapt existing therapies in such a way that the development of resistance and metastases is reduced or even prevented from the outset."
Future Directions and Clinical Trials
Despite the excitement surrounding these results, the research team emphasizes that the method is currently in the preclinical stage. The next essential step is the initiation of prospective clinical trials. These trials will need to determine whether the drug responses observed in the organoids accurately predict the clinical outcomes in patients.
Additionally, the scalability of the process remains a focus. Cultivating organoids requires specialized laboratory settings and highly trained personnel. For this method to become a standard of care in hospitals worldwide, the process of isolating and growing CTCs must be further streamlined and perhaps automated.
The economic impact of this technology also warrants consideration. By identifying effective treatments more quickly and preventing the administration of costly, ineffective therapies, CTC-derived organoid testing could ultimately reduce the financial burden on healthcare systems, despite the initial costs of the laboratory work.
In conclusion, the work of the DKFZ, HI-STEM, and NCT Heidelberg teams represents a significant milestone in the fight against metastatic disease. By turning a simple blood sample into a living model of a patient’s cancer, researchers have moved one step closer to a future where breast cancer is no longer a terminal diagnosis, but a manageable condition addressed through precise, evolution-aware medical strategies. The discovery of the NRG1/FGFR1 bypass mechanism offers a tangible target for the next generation of oncology drugs, providing hope for thousands of patients currently facing therapy-resistant disease.
